Disease · HP_0030955
Addictive alcohol use
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Addictive alcohol use. Diseases, record HP_0030955. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0030955
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Addictive alcohol use
- Open Targets ID
- HP_0030955
- Other names
- Alcohol addiction, Alcoholism
- Highest stage of its drugs
- Phase 3, for 3 of its 13 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GABAPENTIN | CHEMBL940 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMEGA-3 FATTY ACIDS | CHEMBL4298065 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLYCINE | CHEMBL773 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCONEXENT | CHEMBL367149 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GSK-1521498 | CHEMBL4297383 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ICOSAPENT | CHEMBL460026 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BACLOFEN | CHEMBL701 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OPIPRAMOL | CHEMBL370753 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets79
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
| GABRD | GABA-A receptor; anion channel | 2 | GABA-A receptor; anion channel positive modulator | Phase 2/3 | https://conductscience.org/library/genes/2563 | Drugs and targets |
1 to 10 of 79
See all 79 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00183196 | Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone | Phase 3 | 150 | 2013-05-30 | Alcohol Dependence | GABAPENTIN, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT02026011 | Naltrexone for Individuals of East Asian Descent | Phase 2 | 87 | 2019-07-17 | Alcohol Use Disorder | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT01211769 | Effects of Omegas 3 and 6 on Alcohol Dependence | Phase 3 | 80 | 2010-09-29 | Alcohol Dependence | NALTREXONE, OMEGA-3 FATTY ACIDS | Its record names the disease | ClinicalTrials.gov |
| NCT01916941 | Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin | Not applicable | 36 | 2017-10-17 | Alcohol Use Disorder | PRAZOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT00338598 | Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism | Phase 2 | 20 | 2017-04-12 | Alcoholism, Schizophrenia | GLYCINE | Its record names the disease | ClinicalTrials.gov |
| NCT03065998 | Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction | Early phase 1 | 140 | Drug Abuse | BACLOFEN, OPIPRAMOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00014027 | Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress | Phase 1 | 97 | Healthy | DOCONEXENT, ICOSAPENT | Its record names the disease | ClinicalTrials.gov | |
| NCT00226694 | Alcohol and Gender Effects on Stress Circuit Function | Not applicable | 96 | Alcoholism, Stress, Alcohol Dependence | CITALOPRAM | Its record names the disease | ClinicalTrials.gov | |
| NCT01145677 | Efficacy of Topiramate for Hospitalized Patients With Alcoholism | Phase 2/3 | 90 | Alcohol Dependence | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00425711 | Study of Acamprosate in Driving Under the Influence (DUI) Court Participants | Not applicable | 4 | Alcohol Dependence | ACAMPROSATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Naltrexone vs Sugar Pill: deaths from any cause | 0 of 75 | 0 of 74 | 149 | NCT02026011 | Trial comparisons |
| Naltrexone vs Sugar Pill: serious adverse events | 0 of 75 | 0 of 74 | 149 | NCT02026011 | Trial comparisons |
| Prazosin vs Placebo: serious adverse events | 0 of 18 | 0 of 18 | 36 | NCT01916941 | Trial comparisons |
| Glycine vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT00338598 | Trial comparisons |
| Glycine vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT00338598 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0030955
GET https://conductscience.org/api/diseases/v1/HP_0030955/targets?page=2